Algernon Pharmaceuticals Provides Year End Summary of Key Activities
Algernon Pharmaceuticals Provides Year End Summary of Key Activities Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to provide a summary of the Company’s key activities this past calendar year. NP-120 Idiopathic Pulmonary Fibrosis & Chronic Cough Clinical Research Program March 30 – Submitted for ethics approval in Australia for a Phase 2 study of the Company’s re-purposed drug Ifenprodil for IPF and chronic cough. May 6 – … Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “ Company ” or “ Algernon...
Source: investingnews.com